Author:
Lunawat Sandeesha,Bhat Krishnamurthy
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference34 articles.
1. Holloway C, Mueller-Berghaus J, Lima B, Lee S, Wyatt J, Nicholas J, et al. Scientific considerations for complex drugs in light of established and emerging regulatory guidance. Ann N Y Acad Sci. 2012;1276(1):26–36. https://doi.org/10.1111/j.1749-6632.2012.06811.x.
2. Indian Pharma: Transitioning to Specialty Generics [Internet]. Yesbank.in. 2017. https://www.yesbank.in/pdf/indian_pharma_transitioning_to_specialty_generics.pdf. Accessed 12 Nov 2018.
3. Fda.gov. GDUFA II Commitment Letter. FDA- OGD; 2017 p. 14–17.
4. Oner Z, Michel S, Polli J. Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey. Ann N Y Acad Sci. 2017;1407(1):26–38. https://doi.org/10.1111/nyas.13505.
5. Uhl K. Complex Generic Drug Product Development Workshop Opening Remarks. Presentation Presented at; Complex Generic Drug Product Development Workshop, CDER SBIA; 2018.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献